MedTrace Logo

Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study

NCT02303574 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2018-12-11

Study results available
· View outcomes & findings →

Summary

This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of AZD7986 in healthy volunteers

Conditions

  • Safety, Pharmacokinetics, Pharmacodynamics, Food Effect

Interventions

DRUG

AZD7986, oral solution, 1 to 50 mg/mL

Starting dose in single ascending dose part: 5 mg

DRUG

Placebo, oral solution

Matching placebo

Sponsors & Collaborators

Principal Investigators

  • Annelize Koch, Dr · PAREXEL Early Phase Clinical Unit, Level 7, Northwick Park Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ, United Kingdom

  • Bengt Larsson · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-03
Primary Completion
2016-08-03
Completion
2016-08-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303574 on ClinicalTrials.gov